Synergistic clinical outcome assessments for cervical dystonia

颈肌张力障碍的协同临床结果评估

• 批准号: 10624087
• 负责人: David A Peterson
• 金额: $ 20.67万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-07-01 至 2025-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10624087
• 关键词: Acceleration; Anxiety; Botulinum Toxins; Cephalometry; Cervical Dystonia; Clinical; Clinical Trials; Computer Analysis; Computer Vision Systems; Data Set; Disease; Dose Limiting; Dystonia; Exhibits; Face; Fatigue; Focal Dystonias; Future; Head; Head Movements; Image; Intervention; Measures; Mental Depression; Methods; Motor; Multi-Institutional Clinical Trial; Neck; Oral; Outcome; Pain; Patient-Focused Outcomes; Patients; Pharmaceutical Preparations; Positioning Attribute; Posture; Reporting; Rotation; Sample Size; Self Assessment; Self Perception; Severities; System; Technology; Testing; Time; Tremor; Validation; Video Recording; Visual; analog; botulinum neurotoxin injection; botulinum toxin treatment; clinical care; clinical outcome assessment; impression; improved; motor impairment; motor symptom; nervous system disorder; non-motor symptom; participant enrollment; response; side effect; software development; treatment choice; treatment effect; treatment response

The dystonias overall are a rare neurologic disorder. Cervical dystonia (CD), sometimes called “spasmodic torticollis”, is one of the most common forms of dystonia. CD is characterized by the partial loss of voluntary control of the neck musculature producing abnormal postures and/or movements of the head in the form of head tremor. In addition to these overt motor abnormalities, the disorder is also associated with non-motor symptoms including pain, fatigue, anxiety, and depression. Treatment options for CD are suboptimal. Many oral medications have been tried but their efficacy is minimal and limited by dose-dependent adverse side effects. Botulinum neurotoxin (BoNT) injections repeated every 3-4 months are the primary treatment of choice. Although BoNT is highly efficacious for many patients, for a variety of reasons about 1/3 of patients discontinue BoNT treatment, and of those who continue treatment about 1/3 are unsatisfied with the response. Because treatment options are suboptimal, there is an active effort to find better strategies for treating CD, as evidenced by dozens of active trials listed on ClinicalTrials.gov. However, the most common clinical outcome assessment used to measure motor abnormalities – the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) – does not capture head tremor. Also, as with most clinical rating scales, the TWSTRS is an intrinsically subjective assessment and therefore suffers from inter-rater variability. This reduces our power to detect treatment effects in clinical trials. Technology-based objective measures have the potential to circumvent this variability. Advances in computer vision technology have enabled the measurement of head orientation/rotation from 2-D images of the face in conventional video recordings. One of the long-term objectives of our group is to leverage these advances to develop software that can capture and quantify motor abnormalities across multiple types of focal dystonia. We are calling this system the Computational Motor Objective Rater (CMOR). In this project specifically targeting CD, our aims are 1) to evaluate CMOR’s convergent validity with patient reports of severity of abnormal head posture and head tremor and 2) to determine CMOR’s sensitivity to changes in severity associated with interventions. To accomplish these aims, we will conduct CMOR analyses of motor symptoms from video recordings of 100 CD patients enrolled in a separate Dystonia Coalition project to evaluate the variability of efficacy of BoNT. That project will also acquire patient reports in the form of a patient centered outcome with specific questions about the two motor features of CD and the patient’s global impression of change (PGIC) in response to each BoNT treatment. Collectively the results will provide important information about CMOR’s validity and a quantitative basis for sample size estimates for future clinical trials in CD.

肌张力障碍是一种罕见的神经系统疾病。颈肌张力障碍（CD），有时称为